[HTML][HTML] EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin …
L Faoro, PA Singleton, GM Cervantes… - Journal of biological …, 2010 - ASBMB
Non-small cell lung cancer (NSCLC) has a poor prognosis and improved therapies are
needed. Expression of EphA2 is increased in NSCLC metastases. In this study, we
investigated EphA2 mutations in NSCLC and examined molecular pathways involved in
NSCLC. Tumor and cell line DNA was sequenced. One EphA2 mutation was modeled by
expression in BEAS2B cells, and functional and biochemical studies were conducted. A
G391R mutation was detected in H2170 and 2/28 squamous cell carcinoma patient …
needed. Expression of EphA2 is increased in NSCLC metastases. In this study, we
investigated EphA2 mutations in NSCLC and examined molecular pathways involved in
NSCLC. Tumor and cell line DNA was sequenced. One EphA2 mutation was modeled by
expression in BEAS2B cells, and functional and biochemical studies were conducted. A
G391R mutation was detected in H2170 and 2/28 squamous cell carcinoma patient …